Bifidobacterium pseudocatenulatum CECT 7765
Bifidobacterium pseudocatenulatum CECT 7765 has been studied primarily in animal models of diet-induced obesity, with administration examined in relation to metabolic and inflammatory markers, gut microbiota composition, vascular function, and bone health. A 2018 randomized controlled trial in insulin-resistant obese children examined inflammatory status, though the study population and scope are limited. Animal work has also examined liver cirrhosis models. Genome sequencing data are available, and in vitro encapsulation studies have explored delivery formulations. These are research topics, not findings; the papers do not establish that this strain treats or prevents any condition.
Where it's been studied Tags come from a conservative keyword scan of each paper's title, abstract, and summary. A tag is research coverage, not measured effect. How we classify this →
Share of this strain's 13 body-system-tagged papers that concern each system. Research coverage, not measured effect.
Symptoms in the research A tag means the paper's text names the symptom or condition — research coverage, not evidence of benefit. How we classify this →
Share of this strain's 10 symptom-tagged papers that mention each symptom or condition. Research coverage, not evidence of benefit.
Research Study-type filters use AI-classified labels, audited but not guaranteed — check the paper itself before leaning on one. How we classify this →
15 papers reference this strain in the probiotic database.
Discussion
Be the first to comment.
Sign in to join the discussion.
Citations
Selected papers that name this strain.
-
[1]
PMID 30251018 →Bifidobacterium pseudocatenulatum CECT 7765 supplementation improves inflammatory status in insulin-resistant obese children· European Journal of Nutrition · 2018